Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (16 quarters reported)
$217M in Q4 2021 → $55.6M now. Hover for any quarter.
As reported for the quarter ended September 30, 2025. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| Tourmaline Bio Inc | 63.8% | Unchanged | 741,691 | $35.5M |
| Korro Bio Inc | 31.7% | Unchanged | 368,085 | $17.6M |
| Jasper Therapeutics Inc | 4.0% | Unchanged | 928,964 | $2.21M |
| Kezar Life Sciences Inc | 0.6% | Unchanged | 82,871 | $323K |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.
quarter ended September 30, 2025 · filed November 10, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Ventyx Biosciences Inc | Exited | −412,225 | −$882K | — |
| Hillevax Inc | Exited | −372,615 | −$742K | — |
quarter ended June 30, 2025 · filed August 14, 2025
No position changes this quarter.
quarter ended March 31, 2025 · filed May 15, 2025
No position changes this quarter.
quarter ended December 31, 2024 · filed January 28, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Kezar Life Sciences Inc | Exited | −828,711 | −$638K | — |
| Kezar Life Sciences Inc | New | +82,871 | +$557K | 1.1% |
| Hillevax Inc | Trimmed | −186,308 | −$386K | 1.5% |
quarter ended September 30, 2024 · filed November 07, 2024
No position changes this quarter.
quarter ended June 30, 2024 · filed August 13, 2024
No position changes this quarter.
quarter ended March 31, 2024 · filed May 14, 2024
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Icosavax Inc | Exited | −3,510,228 | −$55.3M | — |
| Jasper Therapeutics Inc | New | +928,964 | +$27.3M | 30.4% |
| Jasper Therapeutics Inc | Exited | −8,519,648 | −$6.72M | — |
| Tourmaline Bio Inc | Added | +100,000 | +$2.29M | 18.9% |
| Ventyx Biosciences Inc | Trimmed | −274,145 | −$1.51M | 2.5% |
| Elevation Oncology Inc | Exited | −2,370,142 | −$1.27M | — |
quarter ended December 31, 2023 · filed February 14, 2024
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Korro Bio Inc | New | +368,085 | +$17.6M | 16.2% |
| Tourmaline Bio Inc | New | +641,691 | +$16.8M | 15.4% |
| TT Talaris Therapeutics Inc | Exited | −2,932,606 | −$8.24M | — |
Loading...
